Back to search results

INTERogating Cancer for Etiology, Prevention and Therapy Navigation Study

This study, called INTERogating Cancer for Etiology, Prevention and Therapy Navigation, is an observational study looking at cancer. It aims to understand the causes and markers of cancer by analyzing your genetic material (DNA), RNA, and other samples like blood or tissue. Researchers will use Pan-genomic Testing to look for specific changes in cancer cells and normal cells. The goal is to create a library of samples and information to help prevent, diagnose earlier, or better treat cancer. To join, you need to be at least 18 years old, have a confirmed cancer diagnosis, and have had germline and/or somatic tumor/blood testing ordered by your doctor. This study plans to enroll 500 participants.

Study design
This is an observational study planning to enroll 500 participants. It is not specified if it is randomized or blinded.
What's involved
You would review study details, consent, and provide medical information. Samples like blood, saliva, bone marrow aspirate, or hair would be collected.
Compensation
Not stated in the trial record.
Follow-up
Genomic sequencing of tumor tissue and blood will be measured at baseline, up to 50 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06008392

INTERogating Cancer for Etiology, Prevention and Therapy Navigation

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~500 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:Pan-genomic Testing

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Genomic sequencing of tumor tissue and blood
Measured over Baseline; 50 years

Conditions

Cancer
Cancer Gene Mutation
PAN Gene Mutation
Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT06008392

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Arizona

    Scottsdale, Arizonastudy coordinator listed

    Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Floridastudy coordinator listed

    Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jewel J. Samadder, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has Mayo Clinic medical record number
Confirmed cancer diagnosis
Germline and/or somatic tumor/blood testing has been ordered by the clinical provider (or clinical delegate)
Participant aware of cancer diagnosis
Able to provide informed consent
≥ 18 years old
Ability to provide blood, saliva, bone marrow aspirate or hair follicle sample
Ability to provide archived tissue, if somatic testing has not already been completed
Note: if tissue unavailable participant may still enroll onto the study for the germline collection, or vice versa, if germline has already been completed may still enroll for somatic tissue/blood testing.
Has Mayo Clinic medical record number
Confirmed cancer diagnosis
Germline testing has been ordered by the clinical provider (or clinical delegate)
Participant aware of cancer diagnosis
Able to provide informed consent
≥ 18 years old
Ability to provide blood, saliva, or hair follicle sample
Has Mayo Clinic medical record number,
Confirmed cancer diagnosis,
Somatic tumor/blood testing has been ordered by the clinical provider (or clinical delegate)
Participant aware of cancer diagnosis,
Able to provide informed consent,
≥ 18 years old
Ability to provide archived tissue or blood for somatic tumor genomic profiling, if not already completed.
Has Mayo Clinic medical record number,
Standard of care clinical visit with genetic counselor
Confirmed cancer diagnosis,
Germline testing has been ordered by the clinical provider (or clinical delegate)
Participant aware of cancer diagnosis,
Able to provide informed consent,
≥ 18 years old
Ability to provide blood, saliva, or hair follicle sample
Enrolled in any of the following studies: IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810
Completed Riskguard, OncoExtra, Caris Assure, or Caris MI Profile or any combination of these tests.
Has Mayo Clinic medical record number,
Confirmed cancer diagnosis,
Participant aware of cancer diagnosis
Able to provide informed consent,
≥ 18 years old

Exclusion

Individuals who have situations that would limit compliance with the study requirements
Institutionalized (i.e. Federal Medical Prison)
Individuals who have situations that would limit compliance with the study requirements
Institutionalized (i.e. Federal Medical Prison)
Prior germline genetic testing with a 100+ multi-gene panel within the last 1 year of enrollment
Individuals who have situations that would limit compliance with the study requirements,
Institutionalized (i.e. Federal Medical Prison),
Individuals who have situations that would limit compliance with the study requirements,
Institutionalized (i.e. Federal Medical Prison)
Individuals who have situations that would limit compliance with the study requirements,
Institutionalized (i.e. Federal Medical Prison)

What this trial measures

  • Genomic sequencing of tumor tissue and bloodBaseline; 50 years

    Genomic sequencing of tumor tissue and blood will be performed to determine genomic alterations in germline and somatic cancer-related genes (SNVs, indels, CNVs from DNA and fusions from RNA) to allow the ordering hematologist/oncologist/provider to determine optimal therapy and clinical trial prospective. Researchers across the field of genomic sequencing report findings about new variations in scientific publications and collect it in databases every day. Consequently, any patient's variant of uncertain significance (VUS) result could be reclassified by emerging findings, turning previously unresolved tests into diagnostic answers. Our Translational Omics Program has a system to re-analyze a patient's exome/genome data against these new genetic findings-reviewing data and comparing it with emerging clinical genetic data to facilitate diagnoses.